| Quarterly Financials | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
Revenue  | 251 | 217 | 282 | 190 | 211 | 254 | 247 | 296 | 281 | 293 | 324 | 456 | 381 | 350 | 289 | 367 | 381 | 358 | 251 | 234 | 270 | 508 | 620 | 698 | 853 | 564 | 571 | 551 | 617 | 435 |
| Expenses | 129 | 95 | 147 | 99 | 108 | 126 | 140 | 138 | 166 | 149 | 179 | 206 | 207 | 188 | 179 | 207 | 198 | 181 | 133 | 154 | 180 | 363 | 398 | 439 | 627 | 445 | 435 | 454 | 537 | 421 |
| EBITDA | 122 | 122 | 135 | 91 | 103 | 128 | 107 | 158 | 116 | 144 | 144 | 251 | 174 | 162 | 111 | 160 | 183 | 178 | 118 | 80 | 90 | 145 | 222 | 259 | 226 | 118 | 137 | 97 | 80 | 13 |
| Operating Profit % | 49 % | 52 % | 46 % | 45 % | 41 % | 47 % | 41 % | 50 % | 36 % | 43 % | 40 % | 48 % | 43 % | 45 % | 36 % | 41 % | 47 % | 48 % | 42 % | 30 % | 29 % | 26 % | 34 % | 35 % | 25 % | 19 % | 22 % | 17 % | 13 % | 0 % |
| Depreciation | 6 | 6 | 6 | 6 | 7 | 7 | 8 | 9 | 8 | 9 | 9 | 11 | 10 | 12 | 12 | 12 | 12 | 13 | 12 | 13 | 17 | 31 | 38 | 44 | 54 | 45 | 44 | 47 | 51 | 50 |
| Interest | 2 | 4 | 4 | 8 | 7 | 3 | 3 | 2 | 2 | 2 | 1 | 1 | 2 | 2 | 0 | 1 | 5 | 1 | 1 | 2 | 2 | 10 | 10 | 11 | 10 | 10 | 9 | 9 | 9 | 7 |
| Profit Before Tax | 115 | 113 | 125 | 78 | 89 | 118 | 97 | 148 | 106 | 133 | 134 | 240 | 161 | 149 | 99 | 146 | 166 | 164 | 105 | 66 | 71 | 103 | 174 | 205 | 161 | 63 | 84 | 41 | 20 | -43 |
| Tax | 40 | 21 | 32 | 20 | 15 | 26 | 23 | 34 | 22 | 28 | 37 | 79 | 70 | 41 | 26 | 38 | 42 | 43 | 26 | 19 | 18 | 28 | 36 | 51 | 44 | 16 | 17 | 12 | 12 | 2 |
| Net Profit | 75 | 92 | 93 | 58 | 74 | 92 | 74 | 114 | 83 | 105 | 97 | 160 | 92 | 108 | 72 | 108 | 124 | 121 | 80 | 47 | 53 | 75 | 138 | 154 | 117 | 46 | 66 | 29 | 8 | -45 |
| EPS in ₹ | 5.88 | 7.22 | 3.65 | 4.55 | 5.83 | 3.60 | 2.91 | 4.46 | 3.27 | 4.13 | 3.81 | 6.29 | 3.60 | 4.22 | 2.83 | 4.23 | 4.87 | 4.74 | 3.13 | 1.84 | 2.10 | 1.98 | 3.63 | 4.02 | 3.16 | 1.28 | 1.94 | 0.96 | 0.51 | -0.63 |
Cohance Lifesciences
Cohance Lifesciences
463.95
+16.95
(3.79%)
Market Cap
17,749.20 Cr
PE Ratio
292.22
Volume
22,68,116.00
Day High - Low
474.70 - 445.55
52W High-Low
1,038.90 - 266.70
Key Fundamentals
Market Cap
17,749.20 Cr
EPS
4.69
PE Ratio
292.22
PB Ratio
4.37
Book Value
102.24
EBITDA
397.52
Dividend Yield
0.00 %
Industry
Healthcare Sector
Pharmaceuticals Return on Equity
14.38
Debt to Equity
0.09
Analyst Rating and Forecast
- By Refinitiv from8 analysts
Actual
Company News
View All News
Cohance Lifesciences Limited has uploaded the audio recording of its conference call for the quarter ended June 30, 2026, on its website. The call, held on August 5, 2026, was conducted in compliance with SEBI LODR regulations. Investors can access the recording via the provided link for detailed insights into the company's performance and management commentary.
Cohance Lifesciences Gets FDA 483 With 5 Observations6 days ago
Cohance Lifesciences has received a US FDA Form 483 with five observations pertaining to its Hyderabad facility following an inspection.
Cohance Lifesciences Q1FY27 Results
6 days ago
6 days agoCohance Lifesciences reports a 97.3% drop in standalone net profit to ₹14 crore in Q1FY27, driven by shipment phasing and lower CDMO contribution. Consolidated results show a loss of ₹452 crore.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,942.00 | #1 4,65,950.85 | 38.67 | #1 61,673.90 | 12.69 | #1 11,565 | 26.53 | 51.03 | |
8,578.50 | 2,27,732.22 | 75.10 | 11,067.00 | 13.95 | 2,568 | 65.50 | 77.55 | |
4,886.00 | 1,85,847.73 | 86.72 | 13,886.20 | 20.34 | 2,138 | 3.28 | 49.07 | |
1,191.00 | 1,19,842.47 | 21.82 | 27,657.90 | 17.64 | 5,026 | 7.82 | 68.32 | |
1,463.00 | 1,18,187.77 | 35.15 | 29,044.60 | 2.24 | 3,870 | -39.18 | 55.73 | |
2,278.90 | 1,04,198.72 | #1 18.74 | 29,038.90 | #1 26.75 | 5,356 | 16.00 | 33.95 | |
1,205.00 | 1,00,577.62 | 30.34 | 35,058.60 | 3.90 | 4,158 | -69.10 | 50.59 | |
1,858.00 | 1,00,305.35 | 92.47 | 6,867.80 | 22.01 | 890 | #1 123.93 | 79.87 | |
2,425.00 | 1,00,151.52 | 48.70 | 14,636.40 | 14.85 | 1,938 | 29.13 | 42.12 | |
1,658.00 | 95,397.65 | 25.76 | 34,145.20 | 5.56 | 3,503 | 25.21 | 64.42 |
Growth Rate
Revenue Growth
80.60 %
Net Income Growth
-51.98 %
Cash Flow Change
-19.62 %
ROE
-1.78 %
ROCE
-30.56 %
EBITDA Margin (Avg.)
-50.01 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
| Total Assets | 783 | 1,173 | 1,475 | 1,830 | 1,966 | 2,254 | 3,032 | 5,730 |
| Fixed Assets | 271 | 357 | 441 | 534 | 663 | 670 | 1,713 | 2,263 |
| Current Assets | 390 | 392 | 565 | 1,128 | 1,011 | 1,263 | 889 | 1,796 |
| Capital Work in Progress | 111 | 102 | 96 | 30 | 165 | 179 | 256 | 173 |
| Investments | 7 | 338 | 542 | 598 | 536 | 905 | 337 | 562 |
| Other Assets | 394 | 376 | 395 | 667 | 601 | 501 | 726 | 32 |
| Total Equity & Liabilities | 783 | 1,173 | 1,475 | 1,830 | 1,966 | 2,254 | 3,032 | 5,730 |
| Current Liabilities | 158 | 200 | 220 | 210 | 159 | 107 | 365 | 646 |
| Non Current Liabilities | 35 | 128 | 74 | 92 | 72 | 97 | 826 | 1,050 |
| Total Equity | 590 | 845 | 1,181 | 1,527 | 1,735 | 2,051 | 1,841 | 3,911 |
| Reserve & Surplus | 578 | 832 | 1,155 | 1,502 | 1,710 | 2,025 | 1,671 | 3,873 |
| Share Capital | 13 | 13 | 26 | 26 | 26 | 26 | 26 | 38 |
Cash Flow
| Cash Flow | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 11 | 1 | -5 | 37 | 20 | -18 | 38 |
| Investing Activities | -66 | -414 | -311 | -136 | -195 | -362 | -253 |
| Operating Activities | 50 | 407 | 383 | 330 | 457 | 359 | 288 |
| Financing Activities | 26 | 7 | -76 | -156 | -242 | -14 | 3 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | May 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| Promoter | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 50.10 % | 50.10 % | 50.10 % | 50.10 % | 50.10 % | 66.41 % | 66.41 % | 57.49 % | 57.49 % | 57.49 % | 57.49 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 10.01 % | 10.14 % | 9.54 % | 9.80 % | 10.70 % | 10.84 % | 11.05 % | 7.38 % | 7.23 % | 6.51 % | 6.02 % | 5.59 % | 6.50 % |
| DIIs | 4.30 % | 4.47 % | 4.94 % | 5.24 % | 5.91 % | 6.32 % | 10.52 % | 11.35 % | 11.43 % | 9.23 % | 14.14 % | 15.94 % | 17.24 % | 17.42 % | 16.94 % | 16.68 % | 16.60 % | 11.02 % | 11.40 % | 20.82 % | 21.57 % | 21.79 % | 20.09 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % |
| Public / Retail | 20.87 % | 19.86 % | 19.21 % | 18.38 % | 17.07 % | 16.86 % | 14.69 % | 14.01 % | 12.76 % | 12.80 % | 11.76 % | 10.87 % | 10.51 % | 10.08 % | 9.75 % | 9.81 % | 9.68 % | 6.63 % | 6.40 % | 6.42 % | 6.76 % | 7.04 % | 7.71 % |
| Others | 14.84 % | 15.68 % | 15.86 % | 16.38 % | 17.02 % | 16.82 % | 14.78 % | 14.64 % | 15.81 % | 17.97 % | 4.08 % | 3.04 % | 12.59 % | 12.59 % | 12.50 % | 12.56 % | 12.55 % | 8.55 % | 8.55 % | 8.75 % | 8.16 % | 8.08 % | 8.21 % |
| No of Share Holders | 75,207 | 92,534 | 96,532 | 86,447 | 85,725 | 86,088 | 82,577 | 79,412 | 72,885 | 72,167 | 73,715 | 70,052 | 68,932 | 65,777 | 69,337 | 84,210 | 86,325 | 88,658 | 80,910 | 75,284 | 81,877 | 85,230 | 99,149 |
Dividend History
| Annual Cash Flows | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 5 | 2 | 5 | 6 | 0.00 | 0.00 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 1.01 | 0.32 | 1.06 | 0.89 | 0.00 | 0.00 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 17 Sept 2026 |  Annual General Meeting | NA | 17 Sept 2026 | 425.20 | 447.10 |
| 28 Sept 2020 |  Bonus | 1:1 | 25 Sept 2020 | 383.55 | 383.70 |
| 18 Feb 2021 |  Dividend | ₹ 1.00 /share | 17 Feb 2021 | 486.60 | 494.65 |
| 17 Aug 2021 | Dividend | ₹ 1.00 /share | 13 Aug 2021 | 514.80 | 559.70 |
| 16 Feb 2022 | Dividend | ₹ 1.00 /share | 15 Feb 2022 | 558.50 | 522.45 |
| 16 Feb 2022 | Dividend | ₹ 2.00 /share | 15 Feb 2022 | 558.50 | 522.45 |
| 17 May 2022 | Dividend | ₹ 1.00 /share | 13 May 2022 | 580.15 | 507.45 |
| 17 May 2022 | Dividend | ₹ 1.00 /share | 13 May 2022 | 580.15 | 507.45 |
| 12 Sept 2022 | Dividend | ₹ 1.00 /share | 09 Sept 2022 | 492.90 | 477.85 |
| 12 Sept 2022 | Dividend | ₹ 5.00 /share | 09 Sept 2022 | 492.90 | 477.85 |
| 15 Dec 2023 | Annual General Meeting | NA | 15 Dec 2023 | 572.10 | 673.25 |
| 09 Aug 2024 | Annual General Meeting | NA | 09 Aug 2024 | 848.75 | 990.80 |
| 12 Nov 2024 |  Quarterly Result Announcement | NA | 12 Nov 2024 | 1,197.40 | 1,250.60 |
| 28 Nov 2024 |  Extraordinary General Meeting | NA | 28 Nov 2024 | 1,266.90 | 1,259.05 |
| 12 Feb 2025 | Quarterly Result Announcement | NA | 12 Feb 2025 | 1,148.20 | 1,084.55 |
| 07 May 2025 |  Change Of Name | NA | 07 May 2025 | 1,118.50 | 1,118.50 |
| 28 May 2025 | Quarterly Result Announcement | NA | 28 May 2025 | 1,151.25 | 1,092.20 |
| 13 Aug 2025 | Quarterly Result Announcement | NA | 13 Aug 2025 | 1,002.00 | 949.95 |
| 19 Sept 2025 | Annual General Meeting | NA | 19 Sept 2025 | 980.00 | 912.70 |
| 12 Nov 2025 | Quarterly Result Announcement | NA | 12 Nov 2025 | 869.30 | 691.30 |
| 12 Feb 2026 | Quarterly Result Announcement | NA | 12 Feb 2026 | 537.60 | 355.05 |
| 12 May 2026 | Quarterly Result Announcement | NA | 12 May 2026 | 454.15 | 478.95 |
| 05 Aug 2026 | Quarterly Result Announcement | NA | 05 Aug 2026 | 438.10 | 425.20 |
Announcements
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome4 hrs ago
4 hrs agoAnnouncement under Regulation 30 (LODR)-Newspaper Publication5 days ago
5 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome5 days ago
5 days agoCompletion Of USFDA Inspection6 days ago
6 days agoOutcome Of The Board Meeting6 days ago
6 days agoBoard Meeting Outcome for Outcome Of The Board Meeting6 days ago
6 days agoAllotment Of Equity Shares Pursuant To Exercise Of Stock Options And Grant Of Stock Options To Certain Eligible Employees Of The CompanyJul 23, 2026
Jul 23, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 23, 2026
Jul 23, 2026Board Meeting Intimation for Considering The Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter Ended 30 June 2026Jul 23, 2026
Jul 23, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 07, 2026
Jul 07, 2026Closure of Trading WindowJun 26, 2026
Jun 26, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 26, 2026
Jun 26, 2026Clarification On Volume MovementJun 24, 2026
Jun 24, 2026Clarification sought from Cohance Lifesciences LtdJun 24, 2026
Jun 24, 2026Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011Jun 19, 2026
Jun 19, 2026Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 19, 2026
Jun 19, 2026Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011Jun 19, 2026
Jun 19, 2026Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations 2011.Jun 18, 2026
Jun 18, 2026Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011Jun 18, 2026
Jun 18, 2026Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011Jun 18, 2026
Jun 18, 2026Announcement under Regulation 30 (LODR)-Resignation of DirectorJun 17, 2026
Jun 17, 2026 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportJun 14, 2026
Jun 14, 2026Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotJun 14, 2026
Jun 14, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 02, 2026
Jun 02, 2026Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 30, 2026
May 30, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 25, 2026
May 25, 2026Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 15, 2026
May 15, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 15, 2026
May 15, 2026Shareholder Meeting / Postal Ballot-Notice of Postal BallotMay 14, 2026
May 14, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 13, 2026
May 13, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 13, 2026
May 13, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 12, 2026
May 12, 2026Outcome Of The Board MeetingMay 12, 2026
May 12, 2026Board Meeting Outcome for Outcome Of The Board MeetingMay 12, 2026
May 12, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 06, 2026
May 06, 2026Board Meeting Intimation for To Consider And Approve The Audited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Financial Year Ended March 31 2026.May 06, 2026
May 06, 2026Clarification On Movement In Price Of Equity SharesApr 30, 2026
Apr 30, 2026Clarification sought from Cohance Lifesciences LtdApr 29, 2026
Apr 29, 2026Brief Profile Of Mr. Umang Vohra Chairman And Group CEOApr 27, 2026
Apr 27, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 27, 2026
Apr 27, 2026Board Meeting Outcome for Outcome Of Board MeetingApr 27, 2026
Apr 27, 2026Clarification With Respect To Volume MovementApr 13, 2026
Apr 13, 2026Clarification sought from Cohance Lifesciences LtdApr 13, 2026
Apr 13, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 02, 2026
Apr 02, 2026Appointment of Company Secretary and Compliance OfficerMar 30, 2026
Mar 30, 2026Closure of Trading WindowMar 27, 2026
Mar 27, 2026Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMar 13, 2026
Mar 13, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 06, 2026
Mar 06, 2026Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Feb 24, 2026
Feb 24, 2026Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011Feb 20, 2026
Feb 20, 2026Mutual Fund Holdings
Technical Indicators
RSI(14)
Neutral 58.03
ATR(14)
Less Volatile 16.72
STOCH(9,6)
Neutral 53.92
STOCH RSI(14)
Overbought 96.18
MACD(12,26)
Bullish 1.83
ADX(14)
Weak Trend 23.30
UO(9)
Bearish 46.73
ROC(12)
Uptrend And Accelerating 5.90
WillR(14)
Neutral -35.66
About Cohance Lifesciences
Suven Pharmaceuticals Limited is an Indian biopharmaceutical company incorporated in 2018. It specializes in contract development and manufacturing operations for the global life sciences industry, focusing on New Chemical Entity-based intermediates, Active Pharmaceutical Ingredients, specialty chemicals, and formulated drugs. The company provides custom synthesis, process R&D, scale-up, and contract manufacturing...more
Website
Chairperson NameVivek Sharma
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
